Previous 10 | Next 10 |
2023-11-07 08:27:16 ET More on Fusion Pharmaceuticals Seeking Alpha’s Quant Rating on Fusion Pharmaceuticals Historical earnings data for Fusion Pharmaceuticals Financial information for Fusion Pharmaceuticals For further details see: Fusion Pharma...
Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates Canada NewsWire Preliminary data for FPI-2265 ( 225 Ac-PSMA I&T) in approximately 20 to 30 patients on track for Q1 2024 Data from Cohort 2 of the FPI-1434 ...
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors Canada NewsWire HAMILTON, ON and BOSTON , Oct. 16, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage ...
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers Canada NewsWire Data presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeut...
2023-10-04 09:59:33 ET More on Health Care Select Sector SPDR September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Citi turns cautious on pharmaceuticals and biotech BofA Securities:...
2023-10-03 10:00:05 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...
Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences Canada NewsWire HAMILTON, ON and BOSTON , Sept. 5, 2023 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generat...
2023-08-08 08:06:33 ET Fusion Pharmaceuticals press release ( NASDAQ: FUSN ): Q2 GAAP EPS of -$0.38. Revenue of $0.1M (-83.3% Y/Y). For further details see: Fusion Pharmaceuticals GAAP EPS of -$0.38, revenue of $0.1M
Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates Canada NewsWire FPI-2265 (Ac-PSMA I&T) IND transferred to Fusion; program is enrolling patients and on track for Q1 2024 update Preliminary clinical data prese...
2023-07-17 08:06:31 ET Summary FPI-2265 is being explored in patients with metastatic castration-resistant prostate cancer in the ongoing phase 2 TATCIST trial; Results from this study are expected to be released Q1 of 2024. The global metastatic castrate resistant prostate cancer...
News, Short Squeeze, Breakout and More Instantly...
Fusion Pharmaceuticals Inc. Company Name:
FUSN Stock Symbol:
NASDAQ Market:
Fusion Pharmaceuticals Inc. Website:
Acquisition of Fusion Pharmaceuticals Completed Canada NewsWire HAMILTON , ON and BOSTON , June 4, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), a...
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement Canada NewsWire HAMILTON , ON and BOSTON , May 31, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation ...
Fusion Pharmaceuticals Shareholders Approve Acquisition by AstraZeneca Canada NewsWire HAMILTON, ON and BOSTON , May 29, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiocon...